Figure 1.

Study flowcharts showing groups receiving vaccines at 7- and 14-day (top) or 28- and 56-day (bottom) intervals. Unless otherwise indicated, Ad26.ZEBOV (adenovirus serotype 26 [Ad26]) was administered at a dose of 5 × 10¹⁰ viral particles and MVA-BN-Filo (modified vaccinia Ankara [MVA]) at a dose of 1 × 10⁸ 50% tissue culture infective dose (TCID₅₀). The placebo used was 0.9% saline. Vaccination regimens are shown as “dose 1, dose 2 (booster).” Groups included active and placebo recipients. Groups 1 (MVA,Ad26 [Ad26]) and 10 (MVA,Ad26) are combined; all other groups are shown individually. Abbreviations: hdA626, high-dose Ad26 (1 × 10¹¹ viral particles); hdMVA, high-dose MVA (4.4 × 10⁸ TCID₅₀).